NCT07025954 Planned Delivery at 37 Versus 36 Weeks in Pregnancies With Placenta Previaand Accreta
| NCT ID | NCT07025954 |
| Status | Recruiting |
| Phase | — |
| Sponsor | The Third Affiliated Hospital of Guangzhou Medical University |
| Condition | Placenta Previa |
| Study Type | INTERVENTIONAL |
| Enrollment | 600 participants |
| Start Date | 2025-07-12 |
| Primary Completion | 2027-01-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 600 participants in total. It began in 2025-07-12 with a primary completion date of 2027-01-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Current clinical practice guidelines recommend planned cesarean delivery(CD) at 34-37 weeks of gestation in pregnant women with placenta previa and accreta. Preterm birth may lead to neonatal immaturity, while laterCD may increase the risk of severe hemorrhage and surgery complications. Retrospective studies have shown that indicated CD occurs in approximately1/3 of patients before 36 weeks, with the main trigger being antepartum hemorrhage. However, the risk of antepartum hemorrhage is lower after 36 weeks. Recent study showed that delivery shifted from 34-36 weeks to 37 weeks did not increase therisk of maternal intraoperative/postoperative hemorrhage and emergency CD. To further validate this, we propose to conduct a randomized controlled study comparing the effect of planned delivery management strategies at 37 0/7-37 6/7 weeks of gestation with those at 36 0/7-36 6/7 weekson maternal and fetal outcomes. The aim of this study is to explore whether planned delivery up to 37 weeks in pregnant women with placenta previa and accreta improves neonatal outcomes without increasing maternal obstetric risks.
Eligibility Criteria
Inclusion Criteria: * 28-34 weeks of gestation. * Both ultrasound and MRI indicate placenta previa with placenta accreta spectrum (PAS). * Planned to undergo cesarean delivery at the participating study hospitals. * Agree to participate and sign the informed consent form. Exclusion Criteria: * Multiple gestation. * Other obstetric complications (e.g., preeclampsia, vasa previa), and severe maternal medical conditions (e.g., uncontrolled diabetes, progressive cardiovascular disease, active systemic lupus erythematosus, liver cirrhosis). * Major uterine structural anomalies (e.g., uterine didelphys, Uterine tumors ≥5 cm). * Estimated fetal weight \<3rd percentile for gestational age, major congenital anomalies, intrauterine fetal demise.
Contact & Investigator
Zhijian Wang, MD, PhD
PRINCIPAL INVESTIGATOR
The Third Affiliated Hospital of Guangzhou Medical University
Frequently Asked Questions
Who can join the NCT07025954 clinical trial?
This trial is open to female participants only, aged 18 Years or older, up to 45 Years, studying Placenta Previa. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07025954 currently recruiting?
Yes, NCT07025954 is actively recruiting participants. Contact the research team at nieqingwen@126.com for enrollment information.
Where is the NCT07025954 trial being conducted?
This trial is being conducted at Guangzhou, China, Zhengzhou, China, Chengdu, China, Beijing, China and 2 additional locations.
Who is sponsoring the NCT07025954 clinical trial?
NCT07025954 is sponsored by The Third Affiliated Hospital of Guangzhou Medical University. The principal investigator is Zhijian Wang, MD, PhD at The Third Affiliated Hospital of Guangzhou Medical University. The trial plans to enroll 600 participants.